Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has disclosed that Agenda Item No. 1, ‘Approval of Spin-off Plan’, was approved as originally proposed at the 15th Extraordinary General Meeting of Shareholders held on October 17, 2025.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: Results of Extraordinary General Meeting of Shareholders
- Date of Shareholders’ Meeting: October 17, 2025
- Agenda Matters & Results:
- Reporting Items: Audit Report
- Voting Items:
- Agenda Item No. 1 (Approval of Spin-off Plan): Approved as originally proposed
- Related Disclosures:
- September 11, 2025: Securities Registration Statement (Spin-off)
- September 23, 2025: Prospectus
- October 2, 2025: Resolution on Convening General Meeting of Shareholders
- October 2, 2025: Public Notice of Convening General Meeting of Shareholders
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Subsequent Spin-off Implementation and Official Follow-up Disclosures
This disclosure provides notice that the proposal for approving the spin-off plan was officially passed at the extraordinary general meeting of shareholders.
Following shareholder approval, monitoring the ongoing execution of spin-off procedures in accordance with the approved plan and tracking subsequent official announcements is essential.
Relevant details can be verified in subsequent disclosures regarding the implementation of the approved spin-off plan.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
